Diabetes company Glooko partners with insulin dosing app Hedia
Diabetes Management Society Glooko partners with Copenhagen-based Hedia to integrate its app into Glooko’s remote monitoring platform.
The Hedia Diabetes Assistant allows patients to enter their blood sugar, meals and activity levels and provides bolus insulin dosage recommendations. As part of the partnership, the app will integrate with Glooko’s platform, which allows patients to share diabetes data with their providers, including blood sugar, insulin doses, foods and carbohydrates, exercise, blood pressure and weight.
In the European Union, patients can also use the app with connected insulin pens. Glooko said using the feature would give providers better insight into their patients’ insulin therapy.
The companies plan to launch the integration in Europe in the fourth quarter of this year and the first quarter of 2024.
“We are very pleased to partner with Hedia to deliver this algorithm-based innovation for personalized healthcare for diabetes patients and their care teams,” Glooko CEO Russ Johannesson said in a statement. “The strong clinical data supporting Hedia’s efficacy demonstrates that it could be a viable alternative for patients who do not have access to insulin pumps. This partnership shows how interoperability gives people with diabetes the optimal tools available to help manage their condition and improve health outcomes. such as blood sugar stability.”
THE GREAT TREND
Glooko previously announced integration partnerships with Eli Lily, Sanofi , Novo Nordisk and Japanese medical device company Terumo.
The digital health startup also acquired two other diabetes-focused companies last year. In January 2022, he announced that he had bought Berlin based xbirdmaker of AI-based diabetes care tools.
In March last year, Glooko acquired DIABNEXT based in Parisanother diabetes care platform.
Evelyn Gallego will offer more details during the HIMSS23 session “Data for Health Equity: Improving Maternal Health Outcomes Through Interoperability”. It is scheduled for Wednesday, April 19 from 2:30-3:30 CT at the South Building, Level 1, S105A.
